Semaglutide 

Semaglutide is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer^{[1][2][3][4][5]}.

1. Anti-Aβ_25-35 injury experiment:
Semaglutide (1-100 nM; 24 h) significantly increases the survival rate of SH-SY5Y cells, increases the expression of autophagy-related proteins such as LC3II, Atg7, Beclin-1 and P62, inhibits Bax and upregulated Bcl-2, and protectes neurons by enhancing autophagy, inhibiting apoptosis^[1][2].
2. Oral squamous cell carcinoma (OSCC) cell experiment:
Semaglutide (5-40 μM; 48 h) dose-dependently inhibits the proliferation, migration and invasion of Cal27 and HSC4 cells, upregulates E-cadherin and downregulates Vimentin, activates the P38 MAPK signaling pathway (increased p-P38 expression), and induces cell apoptosis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Oral squamous cell carcinoma (OSCC) xenograft model
Semaglutide (3 μmol/kg; subcutaneous injection; 3 times a week; 3 weeks) significantly inhibits the growth of tumor volume in nude mouse oral squamous cell carcinoma (OSCC) xenograft model, downregulates proliferation markers Ki67 and PCNA, upregulates pro-apoptotic protein Bax and downregulates anti-apoptotic protein Bcl-xL, and induces tumor cell apoptosis by activating the P38 MAPK pathway^[3].
Chronic MPTP-induced Parkinson's disease model
Semaglutide (25 nmol/kg; intraperitoneal injection; once every 2 days; 30 days) improves the chronic MPTP-induced Parkinson's disease model in mice and its motor dysfunction, increases the number of nigral tyrosine (TH)-positive neurons, reduces α-synuclein aggregation and glial activation, and reduces the level of oxidative stress marker 4-HNE^[4].
Metabolic dysfunction-associated fatty liver disease (MASLD) model
Semaglutide (25 μg/kg/week + 100 μg/kg/week; subcutaneous injection; once a week; 11 weeks) reduces body weight, blood glucose and serum liver enzymes (ALT, AST, AP), reduces hepatic triglyceride deposition, improves hepatic steatosis and hepatocyte ballooning, and downregulates the de novo lipogenesis markers Acaca and Scd1 in the mouse metabolic dysfunction-associated fatty liver disease (MASLD) model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4113.58

C₁₈₇H₂₉₁N₄₅O₅₉

910463-68-2

Solid

White to off-white

H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}-​​​EFIAWLVRGRG

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Chang YF, et al. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci. 2020 Nov;81:234-239.  [Content Brief]

  [2]. Liu DX, et al. Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress. Parkinsons Dis. 2022 Jul 13;2022:6813017.  [Content Brief]

  [3]. Wang C, et al. Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. J Cancer Res Clin Oncol. 2025 Mar 7;151(3):103.  [Content Brief]

  [4]. Zhang L, et al. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9(1):157-171.  [Content Brief]

  [5]. Soto-Catalán M, et al. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Int J Mol Sci. 2024 Mar 4;25(5):2961.  [Content Brief]